Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Supernus Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Supernus Pharmaceuticals shares (SUPN) are listed on the NASDAQ and all prices are listed in US Dollars. Supernus Pharmaceuticals employs 563 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$31.66|
|52-week range||$17.20 - $34.29|
|50-day moving average||$27.55|
|200-day moving average||$28.68|
|Wall St. target price||$35.75|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$1.84|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-08)||20.06%|
|1 month (2021-09-17)||16.06%|
|3 months (2021-07-16)||19.70%|
|6 months (2021-04-16)||-0.13%|
|1 year (2020-10-16)||55.27%|
|2 years (2019-10-17)||19.07%|
|3 years (2018-10-17)||48.58|
|5 years (2016-10-17)||53.02%|
Valuing Supernus Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Supernus Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Supernus Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 17x. In other words, Supernus Pharmaceuticals shares trade at around 17x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Supernus Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.47. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Supernus Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Supernus Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $179.7 million.
The EBITDA is a measure of a Supernus Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$571 million|
|Operating margin TTM||26.82%|
|Gross profit TTM||$467.9 million|
|Return on assets TTM||6.25%|
|Return on equity TTM||13.8%|
|Market capitalisation||$1.7 billion|
TTM: trailing 12 months
There are currently 7.7 million Supernus Pharmaceuticals shares held short by investors – that's known as Supernus Pharmaceuticals's "short interest". This figure is 1.8% up from 7.5 million last month.
There are a few different ways that this level of interest in shorting Supernus Pharmaceuticals shares can be evaluated.
Supernus Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Supernus Pharmaceuticals shares currently shorted divided by the average quantity of Supernus Pharmaceuticals shares traded daily (recently around 388834.73417722). Supernus Pharmaceuticals's SIR currently stands at 19.75. In other words for every 100,000 Supernus Pharmaceuticals shares traded daily on the market, roughly 19750 shares are currently held short.
However Supernus Pharmaceuticals's short interest can also be evaluated against the total number of Supernus Pharmaceuticals shares, or, against the total number of tradable Supernus Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Supernus Pharmaceuticals's short interest could be expressed as 0.14% of the outstanding shares (for every 100,000 Supernus Pharmaceuticals shares in existence, roughly 140 shares are currently held short) or 0.1604% of the tradable shares (for every 100,000 tradable Supernus Pharmaceuticals shares, roughly 160 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Supernus Pharmaceuticals.
Find out more about how you can short Supernus Pharmaceuticals stock.
We're not expecting Supernus Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Supernus Pharmaceuticals's shares have ranged in value from as little as $17.2 up to $34.29. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Supernus Pharmaceuticals's is 1.2291. This would suggest that Supernus Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Supernus Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise APOKYN, a product indicated for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO, a product indicated as adjunctive treatment to levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults. In addition, its product candidates include SPN-812, which has completed Phase III clinical trials that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; and SPN-820, a novel product candidate in Phase I clinical trials for treatment resistant depression. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development and option agreement with Navitor Pharmaceuticals, Inc.
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.